Clairity, Inc.

Clairity, Inc. is a Boston-based healthcare technology company specializing in artificial intelligence-driven breast cancer risk assessment. The company develops Clairity Breast, the first FDA-authorized AI platform designed to predict a woman's five-year future risk of developing breast cancer using existing screening mammograms. The platform leverages advanced computer vision and machine learning algorithms to identify risk patterns that are not visible to the human eye, enabling earlier detection and prevention opportunities. Clairity Breast integrates seamlessly into existing mammography workflows without requiring additional imaging or specialized hardware, making it accessible to health systems nationwide. The product targets women beginning at age 35 and has been incorporated into updated National Comprehensive Cancer Network (NCCN) clinical guidelines for breast cancer screening and risk assessment. The company emphasizes equitable risk assessment to improve access to life-saving early detection and prevention strategies across diverse populations. Clairity's regulatory credentials include FDA authorization for its AI diagnostic platform. The company is in a pre-launch phase, partnering with health systems across the United States to implement the solution in clinical settings.